GlassScriptPhysician profile
Charles-Eric T Hotte
NPI 1063615151
$9,499.83
in general payments reported to CMS, 2019-2025
37 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $664 · 2021: $1,051 · 2022: $1,270 · 2023: $1,524 · 2024: $1,542 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,073 · Education: $104 · Gift: $79.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,072.83 |
| Education | $103.72 |
| Gift | $79.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,326.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,209.44 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $1,114.55 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $720.72 | 2019-2025 | |
| Celgene Corporation | $516.32 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $391.84 | 2019-2023 | Sutab |
| Davol INC. | $338.64 | 2024-2025 | Phasix Mesh |
| Ipsen Biopharmaceuticals, INC | $289.54 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $289.13 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $287.26 | 2020-2025 | |
| Redhill Biopharma INC. | $237.24 | 2020-2022 | |
| Lilly USA, LLC | $234.03 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $197.88 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $196.28 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $170.75 | 2022-2025 | Ibsrela |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $123.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $111.35 | 2019-2025 | General - Gi Dilatation, General - Polypectomy |
| Qol Medical, LLC | $85.07 | 2021-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $75.84 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $56.02 | 2019-2023 | Zinplava, Dificid |
| Ucb, INC. | $54.91 | 2019-2020 | |
| Organon LLC | $51.39 | 2021-2024 | Hadlima |
| Ironwood Pharmaceuticals, INC | $48.53 | 2020-2022 | |
| Allergan, INC. | $47.76 | 2019-2020 | |
| Vivus LLC | $45.96 | 2024-2025 | Pancreaze |
| Fresenius Kabi USA, LLC | $37.30 | 2023 | Idacio |
| Intercept Pharmaceuticals, INC. | $33.23 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.93 | 2024 | Cyltezo |
| Novo Nordisk INC | $26.15 | 2025 | Wegovy |
| Medtronic, INC. | $23.31 | 2024 | Gi Genius |
| Biocon Biologics INC | $22.21 | 2025 | Yesintek |
| Shionogi INC | $22.07 | 2020 | |
| Alfasigma USA, INC. | $21.08 | 2020 | |
| Endo Pharmaceuticals INC. | $20.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $16.82 | 2021 | |
| Romark Laboratories, Lc | $4.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles-Eric Hotte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.